张若昕

本人的研究方向是肿瘤分子流行病学，着重研究与肿瘤发生发展相关的遗传生物标志物，主要聚焦肺癌和肝癌等消化道肿瘤的生物标志物发现和机制研究。研究方法主要包括全基因组关联研究，生物信息学和分子生物学等。目前主持的科研项目包括国自然青年科学基金、上海市公共卫生体系建设三年行动计划优秀青年人才，广西重点实验室开放课题。担任多个杂志的审稿人，并于2019年获得由美国抗癌协会和亚洲癌症基金颁发的青年学者奖。科研成果发表在Lancet Respiratory Medicine, International Journal of Cancer, Carcinogenesis, Human Molecular Genetics等多个国际期刊上。

My research field is molecular epidemiology, with focus on the identification of genetic causes of complex disease to functional characterisation of disease-causing genes/variants in cancer. The research approaches include a combination of genome-wide association analysis and other omics studies, post-GWAS bioinformatics and molecular biology methods. My current ongoing grants consist of the National Natural Science Foundation of China, and the Young talent fund under the Three-Year Initiative Plan for Public Health System Construction by Shanghai Municipal Health Commission, etc. I have kept abreast with a broad range of the latest scientific research activities by engaging with wider scientific community and collaborations and served as a regular reviewer for multiple journals.

研究生课程《分子流行病学》

研究生课程《肿瘤流行病学》

2019.06—至今          青年副研究员   复旦大学公共卫生学院  流行病学教研室

2016.01—2019.05   博士后         复旦大学附属肿瘤医院 肿瘤研究所 

2018.07—2018.08   访问学者     美国杜克大学 肿瘤研究中心

2011.09—2015.12   分子医学和遗传学博士 临床药理学系  英国伦敦玛丽女王大学巴兹医学院威廉哈维研究所 

中国抗癌协会 会员

中美抗癌协会亚洲癌症研究基金会的USCACA-AFCR青年学者奖

1. Lei Cheng, Qi Liu, Mengyun Wang, Yanzi Gu, Jialei Wang, Qingyi Wei*,Ruoxin Zhang*. Potentially functional genetic variants in the human leukocyte antigen region predict survival of Chinese patients with non-small-cell lung carcinoma. Carcinogenesis; 2020 Sep; 24;41(9):1203-1212.
2. Dai J*, Lv J*, Zhu M*, Wang Y*, Qin N*, Ma H*, He YQ*, Zhang R*, et al. Identification of risk loci and a polygenic risk score for lung cancer: a large-scale prospective cohort study in Chinese populations. Lancet Respir Med. 2019 Oct; 7(10):881-891; pii: S2213-2600(19)30144-4. doi: 10.1016/S2213-2600(19)30144-4. PMID: 31326317
3. Zhang R, Jia M, Xu Y, Qian D, Wang M, Zhu M, Chang J, Wei Q. An ERCC4 regulatory variant predicts grade-3 or -4 toxicities in patients with advanced non-small cell lung cancer treated by platinum-based therapy. Int J Cancer. 2017 Nov 14. 142(6) 1218-1229, doi: 10.1002/ijc.31153. PMID: 29134637
4. Zhang R^#, Zhou F^#, Cheng L, Yu A, Zhu ML, Wang MY, Zhang ZX, Xiang JQ, Wei Q, Genetic variants in nucleotide excision repair pathway predict survival of esophageal squamous cell carcinoma patients receiving platinum-based chemotherapy. Mol Carcinog. 2018 Jul 23, 57(11):1553-1565. PMID: 30035334
5. Zhang R^#, Jia M^#, Xue H, Xu Y, Wang M, Zhu M, Sun M, Chang J, Wei Q. Genetic variants in ERCC1 and XPC predict survival outcome of non-small cell lung cancer patients treated with platinum-based therapy. Sci Rep. 2017 Sep 6;7(1):10702. doi: 10.1038/s41598-017-10800-5. PMID: 28878296
6. Zhang R, Witkowska K, Guerra A, Ng F, Caulfield M, Ye S. A blood pressure-associated variant of

SLC39A8 gene influences cellular cadmium accumulation and toxicity. Hul Mol Genet. 2016 Sep. 15;25(18):4117-4126. doi: 10.1093/hmg/ddw236. PMID: 27466201

1.国家自然科学基金青年科学基金"XPF基因遗传变异对非小细胞肺癌铂类化疗毒性的影响及其功能研究"

(项目号：81902876）

2. 上海市公共卫生体系建设三年行动计划优秀人才计划 （项目号：GWV-10.2-YQ42)

3. 广西教育部重点实验室开放课题 -"Hedgehog 信号通路基因遗传变异与肝细胞癌预后的关系"（GKE-KF202007)